Phase 2 Study of the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
Status:
Not yet recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This is a randomized, observer-blinded, Phase 2 study evaluating the safety and
immunogenicity of a severe acute respiratory syndrome coronavirus 2 (SARSCoV2) recombinant
spike (rS) (SARS-CoV-2 rS) nanoparticle and quadrivalent hemagglutinin (HA) nanoparticle
influenza vaccine (qNIV) combination vaccine with Matrix-M™ adjuvant; this combination
vaccine is referred to as a COVID-19 and Influenza Combination (CIC) vaccine